鳥居薬品の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/10/26 | 2,950 | 3,015 | 2,950 | 3,000 | +63 | +2.1% | 38,700 |
2022/10/25 | 2,957 | 2,962 | 2,931 | 2,937 | +16 | +0.5% | 31,900 |
2022/10/24 | 2,972 | 2,988 | 2,921 | 2,921 | -17 | -0.6% | 39,000 |
2022/10/21 | 2,949 | 2,953 | 2,927 | 2,938 | -11 | -0.4% | 17,900 |
2022/10/20 | 2,935 | 2,973 | 2,935 | 2,949 | -24 | -0.8% | 18,100 |
2022/10/19 | 2,975 | 3,005 | 2,966 | 2,973 | +10 | +0.3% | 26,000 |
2022/10/18 | 2,976 | 2,979 | 2,948 | 2,963 | +37 | +1.3% | 28,100 |
2022/10/17 | 2,916 | 2,942 | 2,916 | 2,926 | -33 | -1.1% | 15,600 |
2022/10/14 | 2,959 | 2,977 | 2,941 | 2,959 | +31 | +1.1% | 36,100 |
2022/10/13 | 2,940 | 2,944 | 2,915 | 2,928 | -22 | -0.7% | 21,100 |
2022/10/12 | 2,940 | 2,973 | 2,925 | 2,950 | +3 | +0.1% | 39,400 |
2022/10/11 | 2,923 | 2,963 | 2,919 | 2,947 | -8 | -0.3% | 31,200 |
2022/10/07 | 2,917 | 2,960 | 2,915 | 2,955 | -5 | -0.2% | 27,700 |
2022/10/06 | 2,920 | 2,968 | 2,920 | 2,960 | +40 | +1.4% | 38,200 |
2022/10/05 | 2,946 | 2,946 | 2,920 | 2,920 | -5 | -0.2% | 25,600 |
2022/10/04 | 2,903 | 2,937 | 2,903 | 2,925 | +31 | +1.1% | 34,300 |
2022/10/03 | 2,834 | 2,895 | 2,815 | 2,894 | +10 | +0.3% | 44,000 |
2022/09/30 | 2,895 | 2,914 | 2,879 | 2,884 | +27 | +0.9% | 51,900 |
2022/09/29 | 2,806 | 2,859 | 2,806 | 2,857 | +111 | +4% | 44,500 |
2022/09/28 | 2,700 | 2,751 | 2,691 | 2,746 | +30 | +1.1% | 56,400 |
2022/09/27 | 2,743 | 2,758 | 2,712 | 2,716 | -16 | -0.6% | 30,300 |
2022/09/26 | 2,728 | 2,755 | 2,726 | 2,732 | -29 | -1.1% | 30,600 |
2022/09/22 | 2,755 | 2,775 | 2,735 | 2,761 | -37 | -1.3% | 43,300 |
2022/09/21 | 2,785 | 2,804 | 2,751 | 2,798 | -13 | -0.5% | 43,200 |
2022/09/20 | 2,797 | 2,879 | 2,797 | 2,811 | +14 | +0.5% | 66,400 |
2022/09/16 | 2,781 | 2,799 | 2,760 | 2,797 | -11 | -0.4% | 42,700 |
2022/09/15 | 2,840 | 2,842 | 2,794 | 2,808 | -26 | -0.9% | 42,500 |
2022/09/14 | 2,858 | 2,871 | 2,834 | 2,834 | -59 | -2% | 38,300 |
2022/09/13 | 2,865 | 2,895 | 2,865 | 2,893 | +32 | +1.1% | 30,100 |
2022/09/12 | 2,914 | 2,916 | 2,857 | 2,861 | -44 | -1.5% | 30,600 |
2022/09/09 | 2,847 | 2,913 | 2,847 | 2,905 | +71 | +2.5% | 45,900 |
2022/09/08 | 2,810 | 2,877 | 2,810 | 2,834 | +31 | +1.1% | 78,300 |
2022/09/07 | 2,877 | 2,877 | 2,802 | 2,803 | -73 | -2.5% | 34,600 |
2022/09/06 | 2,904 | 2,922 | 2,856 | 2,876 | -30 | -1% | 59,600 |
2022/09/05 | 2,915 | 2,933 | 2,906 | 2,906 | -29 | -1% | 31,700 |
2022/09/02 | 2,991 | 2,991 | 2,922 | 2,935 | -44 | -1.5% | 61,600 |
2022/09/01 | 2,980 | 2,996 | 2,963 | 2,979 | -21 | -0.7% | 61,400 |
2022/08/31 | 2,942 | 3,000 | 2,942 | 3,000 | +19 | +0.6% | 31,300 |
2022/08/30 | 2,960 | 2,981 | 2,955 | 2,981 | +21 | +0.7% | 31,900 |
2022/08/29 | 2,961 | 2,976 | 2,953 | 2,960 | -27 | -0.9% | 32,800 |
2022/08/26 | 2,993 | 3,000 | 2,985 | 2,987 | -6 | -0.2% | 14,900 |
2022/08/25 | 3,005 | 3,015 | 2,993 | 2,993 | -5 | -0.2% | 20,500 |
2022/08/24 | 3,000 | 3,010 | 2,967 | 2,998 | -7 | -0.2% | 51,700 |
2022/08/23 | 3,050 | 3,050 | 3,005 | 3,005 | -75 | -2.4% | 20,100 |
2022/08/22 | 3,065 | 3,085 | 3,050 | 3,080 | +10 | +0.3% | 23,700 |
2022/08/19 | 3,085 | 3,100 | 3,055 | 3,070 | +10 | +0.3% | 19,300 |
2022/08/18 | 3,100 | 3,105 | 3,060 | 3,060 | -55 | -1.8% | 22,600 |
2022/08/17 | 3,110 | 3,130 | 3,095 | 3,115 | +20 | +0.6% | 19,600 |
2022/08/16 | 3,085 | 3,105 | 3,065 | 3,095 | +10 | +0.3% | 17,900 |
2022/08/15 | 3,095 | 3,110 | 3,060 | 3,085 | -10 | -0.3% | 28,400 |
601~
650
件表示中 / 3676件
類似銘柄と比較する
現在ご覧いただいている「鳥居薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
鳥居薬 | 410,500円 | +7.1% | -35.0% | 2.92% | 33.94倍 | 0.95倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
キッセイ薬 | 359,000円 | +14.5% | -2.3% | 2.51% | 13.13倍 | 0.70倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
東和薬品 | 236,700円 | +15.0% | -7.3% | 2.96% | 7.77倍 | 0.73倍 |
|
後発医薬品メーカーで国内2強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
ゼリア新薬 | 213,300円 | +14.2% | +41.0% | 2.16% | 10.45倍 | 1.07倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
サンバイオ | 154,600円 | - | - | 0.00% | - | 71.61倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
市場注目の銘柄
チャート関連のコラム